secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001193125-23-256934
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks announces director Lota Zoth will not seek re-election; nominates oncology leader Nancy Davidson to board
--------------------------------------------------------------------------------

- Director Lota Zoth not standing for re-election at Dec. 7, 2023 annual meeting; will continue as lead independent director until term ends.
- Board nominates Dr. Nancy Davidson for election; if elected, she serves as Class II director with term through 2026 annual meeting.
- Davidson is EVP for Clinical Affairs at Fred Hutchinson Cancer Center, past president of ASCO and AACR, bringing deep oncology expertise.
- If elected, Davidson will receive an initial stock option grant for 50,000 shares under standard non-employee director compensation.
- Company is targeting zanidatamab approval/commercialization and five IND filings before end of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523256934/0001193125-23-256934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523256934/d569983d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-256934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer